secwatch.observer — SEC 8-K summary
======================================

Issuer:     Beta Bionics, Inc. (BBNX)
CIK:        0001674632
Form:       8-K
Filed at:   2025-03-25T23:59:59+00:00
Accession:  0001171843-25-001690
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Beta Bionics Q4 revenue up 145% to $20.4M; FY2025 guidance $80-85M
------------------------------------------------------------------

- Q4 net sales $20.4M (+145% YoY); FY2024 net sales $65.1M (+443% YoY). Installed base 15,298 users (+564%).
- Operating loss Q4 $13.0M (neg 64% of sales); net loss $18.1M. Full year operating loss $45.3M.
- Cash $103.6M at Dec 31, 2024; raised ~$206M net from IPO/private placement in Jan 2025.
- FY2025 guidance: revenue $80-85M, >20% new patient starts from PBP channel, gross margin ≥50%.
- Prime Therapeutics added iLet to national commercial formulary; first-to-market integration with Abbott FreeStyle Libre 3 Plus.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674632/000117184325001690/0001171843-25-001690-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674632/000117184325001690/f8k_032525.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-001690

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer